List view / Grid view
8 October 2014 | By Bristol-Myers Squibb Company
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
3 October 2014 | By GTCbio
From 7-10 October 2014, GTCbio will proudly present its Drug Discovery Week Europe event in the beautiful city of Dublin, Ireland...
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
1 October 2014 | By Thermo Fisher Scientific
Scientists involved in materials characterization, process validation and product failure analysis can gather more valuable data by combining two powerful analytical techniques...
1 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases...
1 October 2014 | By Avacta Life Sciences
Avacta Life Sciences is investing £10m in the launch of Affimers, the engineered alternative to antibodies...
30 September 2014 | By Roche
Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash...
30 September 2014 | By Daiichi Sankyo
Lead compound, Quizartinib, will further build Daiichi Sankyo oncology pipeline...
29 September 2014 | By Horizon Discovery Group
Horizon Discovery Group plc announced it has agreed to acquire Sage Labs Inc...
29 September 2014 | By Caris Life Sciences
Caris Life Sciences announced important new data presented at the European Society for Medical Oncology Annual Conference, highlighting how tumour profiling with Caris Molecular Intelligence can help transform cancer care...
29 September 2014 | By Kymab
Following a US$40 million Series B investment from The Wellcome Trust and the Bill & Melinda Gates Foundation...
29 September 2014 | By SIGMOID PHARMA LIMITED
SIGMOID PHARMA LIMITED and Pendopharm have entered into agreements concerning a licence for exclusive rights to commercialise CyCol® in the Canadian market and an equity investment in SIGMOID...
26 September 2014 | By EATRIS
EATRIS has signed a formal framework agreement with the Roche Partnering Extending Innovation Network (EIN) program...
